Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
about
Modulation of Autophagy by Sorafenib: Effects on Treatment ResponseA combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancerMetformin inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the phosphorylation of Akt.
P2860
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Evaluation of in vivo response ...... -deficient of prostate cancer.
@en
type
label
Evaluation of in vivo response ...... -deficient of prostate cancer.
@en
prefLabel
Evaluation of in vivo response ...... -deficient of prostate cancer.
@en
P2093
P2860
P1476
Evaluation of in vivo response ...... -deficient of prostate cancer.
@en
P2093
Hirotsugu Uemura
Kazuhiro Yoshikawa
Kazuhiro Yoshimura
Kazuto Nishio
Masahiro Nozawa
Nobutaka Shimizu
Takafumi Minami
Takashi Oki
Takayuki Ozeki
Yuji Hatanaka
P2860
P2888
P356
10.1186/S12967-015-0509-X
P577
2015-05-08T00:00:00Z
P5875
P6179
1015294223